The use of GLP-1-agonists was associated with a significantly reduced risk of hospitalisation due to alcohol use disorder. Semaglutide was associated with a 36% lower risk, and liraglutide with a ...

Objective: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have shown notable advancements in managing blood sugar control. Nevertheless, there remains a gap in real-world data regarding the ...

A small study of Sanofi’s lixisenatide has suggested that the GLP-1 agonist could slow down the progression of Parkinson’s disease, pointing to another potential use for the fast-growing drug ...

The study, which is published in eClinicalMedicine, looked at whether a type of diabetes medication, called GLP-1 receptor agonists (GLP-1 RAs), could also be used to help people cut down on drinking.

Some GLP-1 receptor agonists may hold promise as treatments for alcohol use disorder (AUD), a Swedish observational study ...

Copyright: © 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

Semaglutide and liraglutide are associated with reduced AUD and SUD-related hospitalization risks, unlike other GLP-1 agonists and AUD medications. The study followed 227,886 individuals with AUD ...

3 “What they are best known for in the popular media is their effect on weight loss. While older medications for diabetes such as insulin and sulfonylureas predispose to weight gain, GLP-1 receptor ...

The EMA’s safety committee has said that, after a review of available data, it has found no evidence that GLP-1 agonist drugs such as Novo Nordisk’s Ozempic and Eli Lilly’s Trulicity can ...

In addition to ensuring equitable access to the glucagon-like peptide-1 (GLP-1) receptor agonists, the medical community needs to figure out how to keep patients on the drugs long term to fully ...

However, this comparison "needs to be taken with a grain of salt," they said, adding that "the comparators were different: GLP-1 agonist use was compared with the times GLP-1 agonists were not ...